Welcome to Our Website Main Page...

Neuralgene is a biotechnology company with its’ flagship gene therapy, PRCN-829, an neurotropic AAV gene therapy designed to treat the neurodegenerative disorder known as Amyotrophic Lateral Sclerosis (ALS). Neuralgene has partnered with Precision StemCell of Bogota, Colombia to begin studies using image-guided administration of gene therapy to the spinal cord.

Neuralgene has several other AAV gene therapies in its’ R&D pipeline for the treatment of other neurodegenerative diseases such as Parkinson’s and Multiple Sclerosis (MS). Neuralgene plans initial testing of PRCN-829 to begin in Colombia this year. In the future, Neuralgene plans to seek approval from the FDA for trials in the USA.